Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC
Status:
Withdrawn
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, single arm phase II study to evaluate the efficacy and
safety of novel BRAF (B-raf murine sarcoma viral oncogene homolog B1) inhibitor encorafenib
(LGX818) when used as single agent in patients with advanced or metastatic (stage IIIB or IV)
BRAF V600 mutant NSCLC. Patients must have progressed on or after at least one previous
systemic, anti-cancer therapy for locally advanced or metastatic NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer